论文部分内容阅读
阿德福韦酯是由美国Gilead Science公司开发的新型核苷类抗乙型病毒性肝炎药物,已在国外进行了Ⅱ、Ⅲ期临床试验。国外的临床研究资料表明,阿德福韦能有效地抑制HBV DNA的复制,使HBV DNA滴度迅速降低,而且在出现拉米夫定耐药的患者中阿德福韦能继续有效地抑制变异株。我国药品监督管理局于2000年12月批准该药在中国进行临床试验,目前,Ⅰ期临床试验已结束,Ⅱ期临床试验也已在2002年12月正式启动。
Adefovir dipivoxil is a new type of nucleoside anti-HBV drug developed by Gilead Science Company in the United States. Phase II and III clinical trials have been conducted abroad. Data from clinical studies abroad show that adefovir can effectively inhibit the replication of HBV DNA and rapidly reduce the HBV DNA titer, and adefovir can continue to effectively inhibit the mutation in patients with lamivudine-resistant Strain. China Drug Administration approved the drug in December 2000 to conduct clinical trials in China, at present, Phase Ⅰ clinical trials have ended, Phase Ⅱ clinical trials have also been officially launched in December 2002.